Great run at start of pandemic. Difficulty is newer contracts are with health insurers, so margins are lower. Not as sticky a service as you might think. You can join, and then unjoin. Hasn't held up. Stock's a bit broken. Need to see price pattern improve and subscriber base more stable.
(A Top Pick Aug 26/20, Down 30%) Typical stay-at-home name. Growing pains. Last quarter had a wider loss than expected. Still sees 25% revenue growth per year. User base and revenue continue to grow. Valuation is a bit expensive. He's being patient, it's the way of the future.
Price target is $166.85. Platform to get healthcare from a variety of professionals. Has grown revenue significantly, leader in the category of med-tech. Volatile. Yet to be profitable. A number of acquisitions. Still likes it.
It's considered a stay-at-home pandemic play, so investors are avoiding it. He thinks TDOCE is better than that with upside. Let others sell it so you can pick it up cheap.
(A Top Pick Dec 01/20, Down 9.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with TDOC has triggered our stop at $175. To be disciplined, we recommend covering the balance of the position (along with the previous recommended gain of 27.5%). This creates an overall return on investment of 8.9%.
It's for real. He likes their game plan and recent acquisition. Problem is, they face more competition. If people think there'll be an economic book, TDC will underperform. Long term, this will be fine, though, because it was a great business model. Teledoc is part of the solution to save Medicare.
TDOC vs. WLL He likes the industry, especially during Covid. A lot of efficiency gains have been unlocked with telehealth platforms. He prefers TDOC in the US, especially after its recent integration.
(A Top Pick Dec 01/20, Up 27.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with TDOC has achieved its $247 objective. To be disciplined, we recommend covering 50% of the position. We also recommend trailing up the stop to $175 (previously at $140).
Has done well because of stay at home. The way of the future. Virtual visits make a lot of sense. Revenue should continue to grow. Higher beta. Long-term secular growth play.
Stockchase Research Editor: Michael O'Reilly TDOC is a telemedicine provider. Five year sales growth has exceeded 60%. Revenue is expected to double this year and grow another 80% in 2021. Announcements recently of vaccines for COVID-19 has caused a brief pullback in share prices, making this a good time to enter. We would buy this with a stop-loss at $140, looking to achieve $247 -- over 25%. Yield 0% (Analysts’ price target is $247.20)
He expects people will stick with digital doctor consultations, post-Covid, because it's more convenient than an in-person visit. The deal to buy Luvongo was terrific merger, combining the leader of telemedicine with a digital health platform for people with chronic conditions like diabetes. However, the stock has fallen since that deal. Something has made investors nervous. However, recent good vaccine news has helped Teladoc though this was gaining acceptance even before Covid.
It has been a winner so far, despite some pullback recently. It is part of the thematic play that has been accelerated by covid. There are a lot of instances where it is more practical for the practitioner and the client to consult through telemedicine. Adoption will continue to rise over time.
Teladoc Inc is a American stock, trading under the symbol TDOC (previously TDOC-N on Stockchase) on the New York Stock Exchange (TDOC). It is usually referred to as NYSE:TDOC or TDOC
Is Teladoc Inc a buy or a sell?
In the last year, there was no coverage of Teladoc Inc published on Stockchase.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is Teladoc Inc worth watching?
0 stock analysts on Stockchase covered Teladoc Inc in the last year. It is a trending stock that is worth watching.
What is Teladoc Inc stock price?
On 2026-06-05, Teladoc Inc (TDOC) stock closed at a price of $7.05.